FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220743891> ?p ?o ?g. }

• W4220743891 endingPage "281" @default.
• W4220743891 startingPage "275" @default.
• W4220743891 abstract "A positive post-treatment prostate biopsy following definitive radiotherapy carries significant prognostic implications. To determine whether local recurrences after prostate stereotactic body radiation therapy (SBRT) are associated with the presence of and occur more commonly within the region of a PI-RADS 4 or 5 dominant intra-prostatic lesion (DIL) identified on pre-treatment multi-parametric magnetic resonance imaging (MRI). 247 patients with localized prostate cancer treated with SBRT at our institution from 2009–2018 underwent post-treatment biopsies (median time to biopsy: 2.2 years) to evaluate local control. Prostate SBRT (median 40 Gy in 5 fractions). MRIs were read by a single diagnostic radiologist blinded to other patient characteristics and treatment outcomes. The DIL presence, size, location, and extent were then analyzed to determine associations with the post-treatment biopsy outcomes. Among patients who underwent post-treatment biopsies, 39/247 (15.8%) were positive for Gleason-gradable prostate adenocarcinoma, of which 35/39 (90%) had a DIL initially present and 29/39 (74.4%) had a positive biopsy within the DIL. Factors independently associated with post-treatment biopsy outcomes included the presence of a DIL (OR 6.95; p = 0.001), radiographic T3 disease (OR 5.23, p < 0.001), SBRT dose ≥40 Gy (OR 0.26, p = 0.003), and use of androgen deprivation therapy (ADT; OR 0.28, p = 0.027). Among patients with a DIL (N = 149), the only factors associated with post-treatment biopsy outcomes included ≥50% percent cores positive (OR 2.4, p = 0.037), radiographic T3 disease (OR 4.04, p = 0.001), SBRT dose ≥40 Gy (OR 0.22, p < 0.001), and use of ADT (OR 0.21, p = 0.014). Our results suggest that men with PI-RADS 4 or 5 DILs have a higher risk of local recurrence after prostate SBRT and that most recurrences are located within the DIL. We found the presence of a dominant tumor on pre-treatment MRI was strongly associated with residual cancer within the prostate after SBRT and that most recurrences were within the dominant tumor." @default.
• W4220743891 created "2022-04-03" @default.
• W4220743891 creator A5012145979 @default.
• W4220743891 creator A5028673499 @default.
• W4220743891 creator A5034787589 @default.
• W4220743891 creator A5035509789 @default.
• W4220743891 creator A5040962356 @default.
• W4220743891 creator A5044340498 @default.
• W4220743891 creator A5049069950 @default.
• W4220743891 creator A5081611907 @default.
• W4220743891 date "2023-06-01" @default.
• W4220743891 modified "2023-10-18" @default.
• W4220743891 title "Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion" @default.
• W4220743891 cites W1975378530 @default.
• W4220743891 cites W1980600130 @default.
• W4220743891 cites W1992743783 @default.
• W4220743891 cites W1999045406 @default.
• W4220743891 cites W2033645471 @default.
• W4220743891 cites W2050305848 @default.
• W4220743891 cites W2057608803 @default.
• W4220743891 cites W2156261634 @default.
• W4220743891 cites W2156509184 @default.
• W4220743891 cites W2253196302 @default.
• W4220743891 cites W2444188049 @default.
• W4220743891 cites W2769471966 @default.
• W4220743891 cites W2781827966 @default.
• W4220743891 cites W2802674288 @default.
• W4220743891 cites W2907271500 @default.
• W4220743891 cites W2912385586 @default.
• W4220743891 cites W2914880936 @default.
• W4220743891 cites W2928985222 @default.
• W4220743891 cites W2952903287 @default.
• W4220743891 cites W2973514824 @default.
• W4220743891 cites W3008246956 @default.
• W4220743891 cites W3012827461 @default.
• W4220743891 cites W3014131856 @default.
• W4220743891 cites W3101018805 @default.
• W4220743891 cites W3125222626 @default.
• W4220743891 cites W3129679350 @default.
• W4220743891 cites W313065440 @default.
• W4220743891 cites W4252775619 @default.
• W4220743891 doi "https://doi.org/10.1016/j.euo.2022.02.005" @default.
• W4220743891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35307323" @default.
• W4220743891 hasPublicationYear "2023" @default.
• W4220743891 type Work @default.
• W4220743891 citedByCount "3" @default.
• W4220743891 countsByYear W42207438912023 @default.
• W4220743891 crossrefType "journal-article" @default.
• W4220743891 hasAuthorship W4220743891A5012145979 @default.
• W4220743891 hasAuthorship W4220743891A5028673499 @default.
• W4220743891 hasAuthorship W4220743891A5034787589 @default.
• W4220743891 hasAuthorship W4220743891A5035509789 @default.
• W4220743891 hasAuthorship W4220743891A5040962356 @default.
• W4220743891 hasAuthorship W4220743891A5044340498 @default.
• W4220743891 hasAuthorship W4220743891A5049069950 @default.
• W4220743891 hasAuthorship W4220743891A5081611907 @default.
• W4220743891 hasBestOaLocation W42207438911 @default.
• W4220743891 hasConcept C121608353 @default.
• W4220743891 hasConcept C126322002 @default.
• W4220743891 hasConcept C126838900 @default.
• W4220743891 hasConcept C126894567 @default.
• W4220743891 hasConcept C141071460 @default.
• W4220743891 hasConcept C143409427 @default.
• W4220743891 hasConcept C2775934546 @default.
• W4220743891 hasConcept C2776235491 @default.
• W4220743891 hasConcept C2777899217 @default.
• W4220743891 hasConcept C2780192828 @default.
• W4220743891 hasConcept C2781156865 @default.
• W4220743891 hasConcept C2989005 @default.
• W4220743891 hasConcept C509974204 @default.
• W4220743891 hasConcept C71924100 @default.
• W4220743891 hasConceptScore W4220743891C121608353 @default.
• W4220743891 hasConceptScore W4220743891C126322002 @default.
• W4220743891 hasConceptScore W4220743891C126838900 @default.
• W4220743891 hasConceptScore W4220743891C126894567 @default.
• W4220743891 hasConceptScore W4220743891C141071460 @default.
• W4220743891 hasConceptScore W4220743891C143409427 @default.
• W4220743891 hasConceptScore W4220743891C2775934546 @default.
• W4220743891 hasConceptScore W4220743891C2776235491 @default.
• W4220743891 hasConceptScore W4220743891C2777899217 @default.
• W4220743891 hasConceptScore W4220743891C2780192828 @default.
• W4220743891 hasConceptScore W4220743891C2781156865 @default.
• W4220743891 hasConceptScore W4220743891C2989005 @default.
• W4220743891 hasConceptScore W4220743891C509974204 @default.
• W4220743891 hasConceptScore W4220743891C71924100 @default.
• W4220743891 hasIssue "3" @default.
• W4220743891 hasLocation W42207438911 @default.
• W4220743891 hasLocation W42207438912 @default.
• W4220743891 hasOpenAccess W4220743891 @default.
• W4220743891 hasPrimaryLocation W42207438911 @default.
• W4220743891 hasRelatedWork W1963763301 @default.
• W4220743891 hasRelatedWork W2035098213 @default.
• W4220743891 hasRelatedWork W2522846761 @default.
• W4220743891 hasRelatedWork W2728894889 @default.
• W4220743891 hasRelatedWork W2753537866 @default.
• W4220743891 hasRelatedWork W2896276799 @default.
• W4220743891 hasRelatedWork W2915731681 @default.
• W4220743891 hasRelatedWork W3111778365 @default.

• next